J-P Armand - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

J-P Armand

Showing results (41-50 of 150) with videos related to

Pageof 15

Sort By:

European Journal of Cancer (Oxford, England : 1990)|January 1, 1993

Tumour necrosis factor-alpha plasma levels after flavone acetic acid administration in man and mouseG G Chabot, D Branellec, A Sassi, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1992

Pharmacokinetics and metabolism of 4'-iodo-4'-deoxy-doxorubicin in humansJ Robert, J P Armand, S Huet, et al.

Anti-Cancer Drugs|January 12, 2000

Clinical advances with topoisomerase I inhibitors in gastrointestinal malignanciesJ P Armand, D Cunningham, E van Cutsem, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1995

Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patientsD Abigerges, G G Chabot, J P Armand, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 1996

Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studiesJ P Armand, Y M Extra, G Catimel, et al.

Journal De Radiologie|August 1, 1995

[Diagnosis of extrapontine myelinolysis preceding central pontine myelinolysis]J P Armand, V Dousset, S Winnock, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 1997

Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trialsL P Rivory, M C Haaz, P Canal, et al.

Journal of Pharmaceutical and Biomedical Analysis|January 1, 1987

Oxidative biotransformation of the antitumour agent elliptinium acetate: Structural characterization of its human and rat urinary metabolitesB Monsarrat, M Maftouh, G Meunier, et al.

Head & Neck|January 1, 1997

Palliative treatment with low-dose continuous infusion 5-fluorouracil in recurrent and/or metastatic undifferentiated nasopharyngeal carcinoma typeA Fandi, A Taamma, N Azli, et al.

Investigational New Drugs|January 1, 1995

A clinical screening cooperative group phase II evaluation of lobaplatin (ASTA D-19466) in advanced head and neck cancerM Degardin, J P Armand, B Chevallier, et al.

Pageof 15

Search research articles

Showing results (41-50 of 150) with videos related to

Sort By:

Pageof 15

European Journal of Cancer (Oxford, England : 1990)|January 1, 1993

Tumour necrosis factor-alpha plasma levels after flavone acetic acid administration in man and mouseG G Chabot, D Branellec, A Sassi, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 1992

Pharmacokinetics and metabolism of 4'-iodo-4'-deoxy-doxorubicin in humansJ Robert, J P Armand, S Huet, et al.

Anti-Cancer Drugs|January 12, 2000

Clinical advances with topoisomerase I inhibitors in gastrointestinal malignanciesJ P Armand, D Cunningham, E van Cutsem, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1995

Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patientsD Abigerges, G G Chabot, J P Armand, et al.

Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 1, 1996

Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studiesJ P Armand, Y M Extra, G Catimel, et al.

Journal De Radiologie|August 1, 1995

[Diagnosis of extrapontine myelinolysis preceding central pontine myelinolysis]J P Armand, V Dousset, S Winnock, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 1, 1997

Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trialsL P Rivory, M C Haaz, P Canal, et al.

Journal of Pharmaceutical and Biomedical Analysis|January 1, 1987

Oxidative biotransformation of the antitumour agent elliptinium acetate: Structural characterization of its human and rat urinary metabolitesB Monsarrat, M Maftouh, G Meunier, et al.

Head & Neck|January 1, 1997

Palliative treatment with low-dose continuous infusion 5-fluorouracil in recurrent and/or metastatic undifferentiated nasopharyngeal carcinoma typeA Fandi, A Taamma, N Azli, et al.

Investigational New Drugs|January 1, 1995

A clinical screening cooperative group phase II evaluation of lobaplatin (ASTA D-19466) in advanced head and neck cancerM Degardin, J P Armand, B Chevallier, et al.

Pageof 15